Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

The Lancet Infectious Diseases - Tập 20 - Trang 816-826 - 2020
Pedro M Folegatti1, Mustapha Bittaye1, Amy Flaxman1, Fernando Ramos Lopez1, Duncan Bellamy1, Alexandra Kupke2,3, Catherine Mair1, Rebecca Makinson1, Jonathan Sheridan1, Cornelius Rohde2,3, Sandro Halwe2,3, Yuji Jeong4, Young-Shin Park4, Jae-Ouk Kim4, Manki Song4, Amy Boyd1, Nguyen Tran1, Daniel Silman1, Ian Poulton1, Mehreen Datoo1
1The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Institute of Virology, Philipps University of Marburg, Marburg, Germany
3German Center for Infection Research, Thematic Translational Unit Emerging Infections, Marburg, Germany
4International Vaccine Institute, Science Unit, Seoul, South Korea

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Infectious Diseases

Tập 20

816-826

Thông tin tác giả